Canada's Leading Cannabis Biotech

A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids.

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

InMed is utilizing its proprietary bioinformatics assessment tool to identify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases. Our Bioinformatics Tool has been used to identify two new drug candidates that optimize therapeutic benefits of cannabinoids while limiting adverse effects.

InMed’s proprietary: in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.

InMed’s Core Assets

Bioinformatics

Proprietary computer-based drug/disease target screening tool.

Biosynthesis

Proprietary cannabinoid manufacturing system.

Drug Development Pipeline

Expedited Drug Development timelines, conservative clinical budget targeting high unmet medical conditions utilizing disease-specific formulations:

  • INM-750 for Epidermolysis Bullosa – An orphan paediatric disease characterized by extremely fragile skin with no current approved therapies. Potential of ~$1B.
  • INM-085 for Glaucoma – A serious eye disease with a global market of >$5B.

Investment Highlights

Extensive portfolio of assets in dermatology, ocular diseases, additional indications as well as cannabinoid biosynthesis

Set to achieve value-driving, near-term milestones with limited investment:

  • Lead drug candidate in an orphan paediatric disease with high unmet medical need; Completion of formulation development, toxicology and Ph1-2a clinical trials within 24 months from financing
  • Biosynthesis of cannabinoids commercial-ready within 24 months

Experienced team capable of building value in biopharmaceuticals

Compared to peers in the cannabinoid drug development and epidermolysis bullosa space, InMed is has an attractive valuation

Download our Corporate Presentation.

InMed Corporate Brochure, Investor Presentation

Insights

Keep Up to date!

Get all the latest news & information about InMed...